ZURICH, June 2 (Reuters) - Efforts by Novartis to
defend its blockbuster cancer drug Afinitor against competitors
got a boost on Thursday from European regulators, who approved
it for use on certain types of advanced gastrointestinal and
lung neuroendocrine tumours.
Read more
No comments:
Post a Comment